Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J. Sweeney, Andrew J. Martin, Martin Stockler, Stephen Begbie, Leanna Cheung, Kim N. Chi, Simon Chowdhury, Mark Frydenberg, Lisa Horvath, Anthony M. Joshua, Nicola J. Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy Parulekar, David Pook, Martin Neil ReaumeShahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G. Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Narayan Karanth, Ganessan Kichenadasse
Research output: Contribution to journal › Article › peer-review
112Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.